Italia markets closed

Saniona AB (publ) (0RQJ.L)

LSE - LSE Prezzo differito. Valuta in SEK.
Aggiungi a watchlist
3,0550-0,4800 (-13,58%)
Alla chiusura: 04:45PM GMT
Schermo intero
Chiusura precedente3,5350
Aperto3,0700
Denaro0,0000 x N/D
Lettera0,0000 x N/D
Min-Max giorno3,0550 - 3,0700
Intervallo di 52 settimane3,0550 - 3,0700
Volume1.116
Media VolumeN/D
Capitalizzazione526.972
Beta (5 anni mensile)0,76
Rapporto PE (ttm)N/D
EPS (ttm)-7,3900
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Saniona AB’s Nomination Committee for the Annual General Meeting 2023

    PRESS RELEASE November 25, 2022 Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announced the composition of the Nomination Committee for the Annual General Meeting 2023. Pursuant to the instruction and charter for the Nomination Committee adopted by the general meeting, the Nomination Committee shall comprise of three members, which shall be the Chairman of the Board of Directors and two members appointed by the two largest shareholders as of last September. On Septembe

  • GlobeNewswire

    Saniona publishes its interim report for the third quarter of 2022

    Three Months Ended September 30, 2022 (2021)Nine Months Ended September 30, 2022 (2021)Revenue was SEK 2.4 M (2.3 M)Revenue was SEK 12.0 M (7.6 M)Operating profit/loss was SEK 21.8 M (-88.2 M)Net profit/loss was SEK 17.5 M (-93.7 M)Operating profit/loss was SEK -203.1 M (-286.7 M)Net profit/loss was SEK -204.4 M (-281.8 M)Basic earnings/loss per share was SEK 0.28 (-1.50)Basic earnings/loss per share was SEK -3.28 (-4.52)Diluted earnings/loss per share were SEK 0.28 (-1.50)Diluted earnings/loss

  • GlobeNewswire

    Saniona’s anti-inflammatory and anti-fibrotic candidate SAN903 is ready for clinical studies

    PRESS RELEASE November 3, 2022 SAN903 has finalized preclinical development and fulfilled other requirements for clinical developmentPotential first-in-class compound offers a new treatment paradigm for inflammatory and fibrotic diseases Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announced that SAN903 is ready to start the regulatory process for entering Phase 1 clinical trials either by Saniona alone or together with a partner following successful completion of pre